Roxadustat in lupus nephritis: a novel therapeutic signal for multifactorial anaemia
Mario Martín-Portugués, Victor Moreno-Torres, Pedro Durán-del Campo, Lucía Martín- Tesillano, José Portoles, Ana Huerta · 2026
Read Roxadustat in lupus nephritis: a novel therapeutic signal for multifactorial anaemia by Mario Martín-Portugués, Victor Moreno-Torres, Pedro Durán-del Campo, Lucía Martín- Tesillano, José Portoles, Ana Huerta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289222.txt.
Description
Mario Martín-Portugués and colleagues present a 2026 case report on roxadustat for severe anemia in lupus nephritis. Lupus nephritis is kidney damage caused by systemic lupus. The patient was a man in his 50s cared for at Hospital Puerta de Hierro Majadahonda in Madrid, Spain, with biopsy-proven class IV+V disease diagnosed in 2018.
His anemia had many causes at once, including inflammation, poor iron use, immune effects, drug harm, and kidney failure, and he needed transfusions. Roxadustat, a drug that helps the body make red cells and use iron, was given alongside immune therapy. Blood counts then recovered in a marked way. The authors stress caution, since one case with other treatments running cannot prove the drug worked.
Catalog record
| CREATOR | Mario Martín-Portugués, Victor Moreno-Torres, Pedro Durán-del Campo, Lucía Martín- Tesillano, José Portoles, Ana Huerta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8045 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |